Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Acta Neuropathologica

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s004010100423PMID 11837744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004influential reference
• Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  2002cited by this paper
• Nonsaturable Binding Indicates Clustering of Tau on the Microtubule Surface in a Paired Helical Filament-like Conformation*

  2000cited by this paper
• Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.

  1999cited by this paper
• Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: implications for MAP kinase activation in Alzheimer disease.

  1999cited by this paper
• Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

  1999cited by this paper
• Phosphorylation of tau protein by recombinant GSK‐3β: pronounced phosphorylation at select Ser/Thr‐Pro motifs but no phosphorylation at Ser262 in the repeat domain

  1999cited by this paper
• The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains.

  1999cited by this paper
• The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease.

  1998influential reference
• Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation.

  1998influential reference
• Tau in Alzheimer's disease.

  1998cited by this paper
• Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites.

  1997cited by this paper
• MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption.

  1997cited by this paper
• A Conformation‐ and Phosphorylation‐Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease

  1997influential reference
• Neuropathological Assessment of Alzheimer's Disease: The Experience of the Consortium to Establish a Registry for Alzheimer's Disease

  1997cited by this paper
• Characterization of mAb AP422, a novel phosphorylation‐dependent monoclonal antibody against tau protein

  1996cited by this paper
• Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356.

  1996cited by this paper
• Phosphorylation of Microtubule-associated Proteins MAP2 and MAP4 by the Protein Kinase p110

  1996cited by this paper
• Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.

  1996cited by this paper
• Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase.

  1995cited by this paper
• Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205.

  1995cited by this paper
• A huntingtin-associated protein enriched in brain with implications for pathology

  1995cited by this paper
• Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells.

  1995cited by this paper
• Protein Phosphatase 2A Is the Major Enzyme in Brain that Dephosphorylates τ Protein Phosphorylated by Proline‐Directed Protein Kinases or Cyclic AMP‐Dependent Protein Kinase

  1995cited by this paper
• Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau (*)

  1995cited by this paper
• Microtubule-associated Protein/Microtubule Affinity-regulating Kinase (p110mark)

  1995cited by this paper
• Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein.

  1995cited by this paper
• Hyperphosphorylation of tau in PHF.

  1995cited by this paper
• Tau protein and Alzheimer's disease.

  1994cited by this paper
• Differential effect of phosphorylation and substrate modulation on tau's ability to promote microtubule growth and nucleation.

  1994cited by this paper
• Assembly of Alzheimer‐like filaments from full‐length tau protein

  1994cited by this paper
• Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.

  1994cited by this paper
• Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404

  1994cited by this paper
• Tau Protein and the Neurofibrillary Pathology of Alzheimer's Disease

  1993cited by this paper
• Phosphorylation of tau by cyclic-AMP-dependent protein kinase.

  1993cited by this paper
• The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

  1993cited by this paper
• Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding.

  1993cited by this paper
• Abnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and cdk5

  1993cited by this paper
• Microtubule‐associated Protein Tau, Paired Helical Filaments, and Phosphorylation a

  1993cited by this paper
• Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau.

  1992cited by this paper
• Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau

  1992cited by this paper
• Immunological and conformation characterization of a phosphorylated immunodominant epitope on the paired helical filaments found in Alzheimer's disease.

  1992cited by this paper
• Immunological and conformational characterization of a phosphorylated immunodominant epitope on the paired helical filaments found in Alzheimer's disease

  1992cited by this paper
• The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease

  1992cited by this paper
• Amyloid, dementia and Alzheimer's disease.

  1992cited by this paper
• The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region.

  1992cited by this paper
• Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

  1992cited by this paper
• The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease.

  1991cited by this paper
• Neurofibrillary tangles and beta-amyloid deposits in Alzheimer's disease.

  1991cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Neurofibrillary tangles and β-amyloid deposits in Alzheimer's disease

  1991cited by this paper
• A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis.

  1990cited by this paper
• Tau protein and Alzheimer's disease.

  1990cited by this paper
• Phosphorylation characteristics of the A68 protein in Alzheimer's disease.

  1990cited by this paper
• CORTICAL AND SUBCORTICAL ARGYROPHILIC GRAINS CHARACTERIZE A DISEASE ASSOCIATED WITH ADULT ONSET DEMENTIA

  1989cited by this paper
• Amyloid plaques, neurofibrillary tangles and their relevance for the study of Alzheimer's disease.

  1989cited by this paper
• The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease.

  1989cited by this paper
• Diagnosis of Alzheimer's disease.

  1988cited by this paper
• Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau.

  1988cited by this paper
• Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes.

  1987cited by this paper
• Diagnosis of Alzheimer's disease.

  1985cited by this paper
• The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and "rod-like" structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex.

  1968cited by this paper
• THE FINE STRUCTURE OF SOME INTRAGANGLIONIC ALTERATIONS

  1968cited by this paper

• Conformation-specific monoclonal antibodies reveal early Tau structural intermediates in Alzheimer's disease.

  2026cites this paper
• Advances in Alzheimer's disease: mechanistic insights and therapeutic targets.

  2026cites this paper
• The effects of chronic cannabidiol administration on brain pathology and behavioral deficits found in the tau P301s-line PS19 mouse model of Alzheimer's disease.

  2026cites this paper
• Aging and Alzheimer’s: the critical role of mitochondrial dysfunction and synaptic alterations

  2026cites this paper
• Oxidized MIF is an Alzheimer’s disease drug target relaying external risk factors to tau pathology

  2025cites this paper
• Neuroprotective potential of novel CARTp analogs in the hippocampus of THY-Tau22 mouse model of Tau pathology.

  2025cites this paper
• Integrated dopamine sensing and 40 Hz hippocampal stimulation improves cognitive performance in Alzheimer’s mouse models

  2025cites this paper
• Adeno-Associated Viral Gene Delivery of Wild-Type Human Tau Induces Progressive Hyperphosphorylation and Neuronal Cell Death in the Hippocampi of Middle-Aged Rats

  2025influential citation
• Elevated 24-hydroxycholesterol levels counteract okadaic acid-induced tau hyperphosphorylation and neuronal morphology impairment.

  2025cites this paper
• Convolutional neural network-derived neurofibrillary tangle classifiers: Investigative tools to identify maturation levels and explore post-translational modifications using laser capture microdissection coupled mass spectrometry.

  2025cites this paper
• Tau aggregation results in an impaired ability to counteract microtubule destabilization via specific combinatorial tau phosphorylation patterns

  2025cites this paper
• Global Deficiency of Alzheimer’s Disease Risk Gene Il1rap Reduces Pathological Tau in a Mouse Model of Systemic Inflammation

  2025cites this paper
• The Neurofibrillary Tangle Maturity Scale: A Novel Framework for Tangle Pathology Evaluation in Alzheimer’s Disease

  2025cites this paper
• Neocortical tau propagation is a mediator of clinical heterogeneity in Alzheimer’s disease

  2025cites this paper
• Tau and tauopathies across primate species: implications for modeling neurodegenerative disorders

  2025cites this paper
• Assessing Co‐Localization of ITM2B With Alzheimer's Disease and Limbic‐Predominant Age‐Related TDP‐43 Encephalopathy Neuropathologic Changes

  2025cites this paper
• Cytoskeletal Proteins and Alzheimer’s Disease Pathogenesis: Focusing on the Interplay with Tau Pathology

  2025cites this paper
• Amyloid-β oligomers induced AD-like pathological changes in human cerebral organoids

  2025cites this paper
• Sorafenib promotes the E3 ubiquitin ligase FBXW7 to increase tau degradation and ameliorate tauopathies

  2025cites this paper
• Biomarker-related phospho-tau217 appears in synapses around Aβ plaques prior to tau tangle in cerebral cortex of preclinical Alzheimer's disease.

  2025cites this paper
• The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology

  2025cites this paper
• Immunoelectron microscopy and biochemical studies using three anti-tau antibodies in human brains: associations between pTau and ribosomes

  2025cites this paper
• N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer disease

  2025cites this paper
• Phospho-proteome profiling in human neurons reveals targets of TBK1 in ALS/FTD-associated autophagy networks.

  2025cites this paper
• Morphological and Hyperphosphorylation Transitions of Nanoscale Tau Aggregates in Alzheimer's Disease

  2025cites this paper
• The calpain-mediated proteolytic cleavage peptide P10 modulates Tau phosphorylation in Alzheimer's disease.

  2025cites this paper
• Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease

  2025cites this paper
• Role of saturated fatty acid metabolism in posttranslational modifications of the Tau protein

  2025cites this paper
• Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse.

  2025cites this paper
• Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery

  2025cites this paper
• Mechanism of RNA Oxidation and Its Inhibitor Involved in Ang II‐Induced Cardiomyocyte Hypertrophy

  2025cites this paper
• pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model

  2025cites this paper
• Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease

  2025cites this paper
• The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer’s disease

  2025cites this paper
• Tau Clearance Reverses Neuronal Dysfunction in Both Young and Aged C. elegans

  2025cites this paper
• Saikosaponin C ameliorates tau-related pathology by modulating oxidative stress and MAPK axis in Alzheimer's disease.

  2025cites this paper
• New Research on Biomarkers in Alzheimer's Continuum.

  2025cites this paper
• CRISPR/Cas9-Based therapeutics as a promising strategy for management of Alzheimer’s disease: progress and prospects

  2025cites this paper
• 14-3-3ζ protein prevents formation of GSK3β-phosphorylated Tau protein fibrils.

  2025cites this paper
• Constant light exposure promotes pathogenic tau hyperphosphorylation and phenotypic manifestations in Drosophila disease models.

  2025cites this paper
• Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation

  2025cites this paper
• Post-Translationally Modified Proteoforms as Biomarkers: From Discovery to Clinical Use.

  2025cites this paper
• Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease

  2025cites this paper
• Tauopathies: Calmodulin Regulates Tau Hyperphosphorylation and Its Transformation into Disease-Specific Aggregates

  2025cites this paper
• A role for the autophagy receptor NBR1 in the degradation of tau aggregates.

  2025cites this paper
• Impact of hyaluronic acid-modified hafnium metalorganic frameworks containing rhynchophylline on Alzheimer’s disease

  2025cites this paper
• GPC5 expression highlights astrocytic heterogeneity and divergent hippocampal responses in Alzheimer’s and Parkinson’s Dementia

  2025cites this paper
• Lithium mitigates hippocampal tau pathology in a rodent model of traumatic brain injury

  2025cites this paper
• Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease

  2025cites this paper
• Glucose enrichment reduces lifespan and promotes tau phosphorylation in human tau-expressing C. elegans, unaffected by O-β-GlcNAcylation induction

  2025cites this paper
• Selection of five different types of animal models of Alzheimer’s disease: based on pathological similarity and research objectives

  2025cites this paper
• Biochemical characterization of Tau protein changes and amyloid dynamics in a novel non-transgenic rat model of tauopathy

  2025cites this paper
• Tau clearance reverses touch neuron dysfunction in both young and aged C. elegans

  2025cites this paper
• Unraveling tau's fold: Structural dynamics in Alzheimer's pathogenesis.

  2025cites this paper
• Targeting of phosphorylated tau at threonine 181 by a Qβ virus‐like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques

  2025cites this paper
• Phospho-tau Ser356 is mostly confined to pre-NFT neurons in Alzheimer’s pathology

  2025cites this paper
• Effects of cranial X-ray irradiation in Presymptomatic 3 × Tg-AD mice.

  2025cites this paper
• Amylin exacerbates tau pathology in the visual cortex of diabetic mice by impairing lysosomal activity

  2025cites this paper
• α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies

  2025cites this paper
• Isoliquiritigenin attenuated cognitive impairment, cerebral tau phosphorylation and oxidative stress in a streptozotocin-induced mouse model of Alzheimer's disease.

  2025cites this paper
• Unraveling Molecular Targets for Neurodegenerative Diseases Through Caenorhabditis elegans Models

  2025cites this paper
• Protein Phosphatase 5-Recruiting Chimeras for Accelerating Tau Dephosphorylation.

  2025cites this paper
• Microtubule‐affinity regulating kinase family members distinctively affect tau phosphorylation and promote its toxicity in a Drosophila model

  2024cites this paper
• N-Terminal Proline Editing for the Synthesis of Peptides with Mercaptoproline and Selenoproline: Mechanistic Insights Lead to Greater Efficiency in Proline Native Chemical Ligation.

  2024cites this paper
• Distinct plasma phosphorylated-tau proteins profiling for the differential diagnosis of mild cognitive impairment and Alzheimer's disease by plasmonic asymmetric nanobridge-based biosensor.

  2024cites this paper
• Protein complexes from mouse and chick brain that interact with phospho-KXGS motif tau/microtubule associated protein antibody

  2024cites this paper
• Biomarker-based staging of Alzheimer disease: rationale and clinical applications

  2024cites this paper
• Distinct tau and alpha-synuclein molecular signatures in Alzheimer’s disease with and without Lewy bodies and Parkinson’s disease with dementia

  2024cites this paper
• Characterization of preclinical Alzheimer’s disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology

  2024cites this paper
• Passive immunotherapy for Alzheimer's disease.

  2024cites this paper
• Palmitic Acid Induces Posttranslational Modifications of Tau Protein in Alzheimer’s Disease–Related Epitopes and Increases Intraneuronal Tau Levels

  2024cites this paper
• Pathologic burden goes with the flow: MRI perfusion and pathologic burden in frontotemporal lobar degeneration due to tau

  2024cites this paper
• Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer’s disease, and epilepsy

  2024cites this paper
• Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease.

  2024cites this paper
• Long‐term exposure to excessive norepinephrine in the brain induces tau aggregation, neuronal death, and cognitive deficits in early tau transgenic mice

  2024cites this paper
• Early CA2 Tau Inclusions Do Not Distinguish an Age-Related Tauopathy from Early Alzheimer’s Disease

  2024cites this paper
• Alterations in the brain lipidome of Alzheimer's disease donors with rare TREM2 risk variants

  2024cites this paper
• Unique Pathology in the Locus Coeruleus of Individuals with Down Syndrome

  2024cites this paper
• Characterization of Olive Oil Phenolic Extracts and Their Effects on the Aggregation of the Alzheimer’s Amyloid-β Peptide and Tau

  2024cites this paper
• The role of the FKBP51–Hsp90 complex in Alzheimer’s disease: An emerging new drug target

  2024cites this paper
• Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy

  2024cites this paper
• Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice

  2024cites this paper
• Pin1-catalyzed conformational regulation after phosphorylation: A distinct checkpoint in cell signaling and drug discovery

  2024cites this paper
• The UFMylation pathway is impaired in Alzheimer’s disease

  2024cites this paper
• Ketamine administration causes cognitive impairment by destroying the circulation function of the glymphatic system.

  2024cites this paper
• Identification of retinal oligomeric, citrullinated, and other tau isoforms in early and advanced AD and relations to disease status

  2024cites this paper
• Characterization of neurofibrillary tangle immunophenotype signatures to classify tangle maturity in Alzheimer's disease

  2024cites this paper
• Plasma p‐tau immunoassays in clinical research for Alzheimer's disease

  2024cites this paper
• Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation

  2024cites this paper
• Lipidized analogues of the anorexigenic CART (cocaine- and amphetamine-regulated transcript) neuropeptide show anorexigenic and neuroprotective potential in mouse model of monosodium-glutamate induced obesity.

  2024cites this paper
• Histological and Memory Alterations in an Innovative Alzheimer’s Disease Animal Model by Vanadium Pentoxide Inhalation

  2024cites this paper
• Mark4 ablation attenuates pathological phenotypes in a mouse model of tauopathy

  2024cites this paper
• Tau accumulation is cleared by the induced expression of VCP via autophagy

  2024cites this paper
• Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer’s disease

  2024cites this paper
• Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs.

  2024cites this paper
• The role of the Pin1-cis P-tau axis in the development and treatment of vascular contribution to cognitive impairment and dementia and preeclampsia

  2024cites this paper
• Super-Resolution Imaging Uncovers Nanoscale Tau Aggregate Hyperphosphorylation Patterns in Human Alzheimer’s Disease Brain Tissue

  2024cites this paper
• Phosphorylation of Tau Protein by CDK2/cyclin A and GSK3β Recombinant Kinases: Analysis of Phosphorylation Patterns by Nuclear Magnetic Resonance Spectroscopy.

  2024cites this paper
• Mitochondria-tau association promotes cognitive decline and hippocampal bioenergetic deficits during the aging.

  2024cites this paper
• Age-dependent impact of streptozotocin on metabolic endpoints and Alzheimer's disease pathologies in 3xTg-AD mice.

  2024cites this paper